A phase 2 study of Pfizer’s atirmociclib has hit its primary endpoint, providing evidence that the CDK4 inhibitor improves progression-free survival (PFS) in second-line metastatic breast cancer. But ...
As pharmas like Eli Lilly and Roche bolster their biotech offerings, Pfizer is snuffing out its program designed to incubate new innovations from select companies, dubbed Pfizer Ignite. The Ignite ...
Pfizer’s revenue reached $100 billion a few years ago, driven by its dominance in coronavirus treatments and prevention. In recent times, it’s faced a drop in that demand and losses of exclusivity ...
March 17 (Reuters) - Pfizer (PFE.N), opens new tab said on Tuesday its experimental combination reduced the risk of disease progression or death by 40% in patients with breast cancer. Here are some ...
March 23 (Reuters) - Pfizer (PFE.N), opens new tab and Valneva (VLS.PA), opens new tab said on Monday their Lyme disease vaccine showed more than 70% efficacy in a late-stage study, even as it missed ...
Pfizer Inc. is undervalued at 8-9× forward earnings, offering a nearly 7% dividend yield and significant upside potential. Recent acquisitions, especially Seagen, position PFE for robust growth, with ...
Eli Lilly is making investments in China, Japan and South Korea. Pfizer has broken into obesity thanks to a Chinese nod won by its local partner Sciwind Biosciences. Astellas' CEO attributed a ...
Study met primary endpoint, demonstrating statistically significant increase in the percentage of participants achieving EASI-75 at Week 16 across all doses tested, compared to placebo Tilrekimig ...
March 9 (Reuters) - U.S. drugmaker Pfizer said on Monday its experimental drug for a chronic skin disease met the main goal in a mid-stage study. Here are some details: * The patients treated with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results